Clinical evaluation of Kushmandak Rasayana in the management of Chronic Bronchitis (Kaphaja kasa) - CKMCB

Central Council for Research in Ayurvedic Sciences CCRAS0 个研究点目标入组 195 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Patients of either sex aged between 18 to 70 years.
•2 Patients with documented history of stable Chronic Bronchitis having persistent cough that produces sputum and mucus most of the days, for >= three months per year for >= 2 consecutive years.
•3 Patients having FEV 1 between 50% -80% of predicted value.
•4 Patient willing and able to participate in the study for 14 weeks.

•1 Presence of other pulmonary diseases or allergies like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Bronchial Asthma, Cystic fibrosis, Tuberculosis, Lung cancer, Pulmonary eosinophilia etc.
•2 Patients having pulmonary infections other than Chronic Bronchitis.
•3 Diabetes Mellitus
•4 Patients on prolonged (over 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•5 Patients suffering from major systemic illness necessitating long term drug treatment
•(Rheumatoid arthritis, Tuberculosis, Psycho Neuro Endocrinal disorders, etc.)
•6 Patients with past history of unstable cardiovascular diseases.
•7 Patients with concurrent serious hepatic disorder defined as Aspartate AminoTransferase (AST) and or Alanine Amino Transferase (ALT), defined as over 2 times upper normal limit or Renal Disorders (defined as Serum Creatinine more then 1.2 mgdL).
•8 Alcoholics and or drug abusers.
•9.History of hypersensitivity to the trial drug or any of its ingredients.
•10 Patients who have completed participation in any other clinical trial during the past
•six months.
•11 Pregnant or lactating women.
•12 Any other condition which the Investigator thinks may jeopardize the study.

发起方

Central Council for Research in Ayurvedic Sciences CCRAS